Avid Bioservices Inc (CDMO)

[pphmtoolong]

Corp, let's take a look at a few facts:

Revenues in Avid's market segment are growing rapidly,

Avid's revenues have grown 40% per year for years,

Avid is about to begin commercial production in its second site and actively preparing to get a third site going,

Peregrine revenue predictions for the year, which is almost over, have been increased by roughly $10 million dollars,

Peregrine management re-iterated break even 15 months from year's end.

Oh, and bavi-exosome diagnostics may be worth a parntership, and Memorial Sloan Kettering among others seems to thing Bavi-immunotherapy is worth a trial.

Not bad for a company struggling to maintain NASDAQ listing.

After listening to the CC, I have no concerns regarding Avid's gross profit percentages going forward. My CPA certificate might lend a modicum of credibility to my confidence.